Statistics for Intra-Cellular Therapies (id:7303 ITCI)

Valuation metrics

Market cap

9.08B

Enterprise value

7.85B

Trailing P/E (ttm)

-58.66

Forward P/E

329.38

PEG ratio

329.38

Price/Sales (ttm)

14.79

Price/Book (mrq)

7.93

Enterprise Value/Revenue

12.79

Enterprise Value/EBITDA

-64.81

Overview

Shares outstanding

106.02M

Float

103.74M

Shares short

2.36M

% Held by insiders

0.02%

% Held by institutions

0.96%

Average volume (10 days)

667.59K

Average volume (90 days)

Price summary

52-Week low

58.14

52-Week high

93.45

52-Week change

30.62%

Beta

0.97

50-Day moving average

78.43

200-Day moving average

73.04

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-14.07%

Operating margin

-22.15%

Operational effectiveness

Return on assets

-7.44%

Return on equity

-9.90%

Income statement

Revenue (ttm)

6.10

Revenue per share (ttm)

6.10

Quarterly revenue growth (yoy)

Gross profit (ttm)

428.43M

EBITDA

-121,086,000.00

Net income to common (ttm)

-86,370,000.00

Diluted EPS (ttm)

-0.87

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

1.01B

Total cash per share (mrq)

9.49

Total debt (mrq)

17.71M

Total Debt/Equity (mrq)

1.55

Current ratio (mrq)

765.60%

Book value per share (mrq)

10.80

Cash flow

Cash flow statement

-62,160,000.00

Levered free cash flow (LFCF)

-6,946,125.00